

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
15 July 2021 (15.07.2021)



(10) International Publication Number
WO 2021/142212 A1

(51) International Patent Classification:

A61K 39/235 (2006.01) C07K 14/035 (2006.01)
C07K 14/02 (2006.01) C12N 15/861 (2006.01)

(21) International Application Number:

PCT/US2021/012630

(22) International Filing Date:

08 January 2021 (08.01.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/958,809	09 January 2020 (09.01.2020)	US
62/958,827	09 January 2020 (09.01.2020)	US
62/967,104	29 January 2020 (29.01.2020)	US
62/967,242	29 January 2020 (29.01.2020)	US
63/064,506	12 August 2020 (12.08.2020)	US
63/064,571	12 August 2020 (12.08.2020)	US
63/112,202	11 November 2020 (11.11.2020)	US
63/112,219	11 November 2020 (11.11.2020)	US

(71) Applicants: **VIRION THERAPEUTICS, LLC** [US/US];
7 Creek Bend Court, Newark, Delaware 19711 (US). **THE
WISTAR INSTITUTE** [US/US]; 3601 Spruce Street,
Philadelphia, Pennsylvania 19104 (US).


(72) Inventors: **ERTL, Hildegund CJ**; c/o The Wistar Insti-
tute, 3601 Spruce Street, Philadelphia, Pennsylvania 19104
(US). **MAGOWAN, Colin Stephen**; c/o Virion Therapeu-
tics, LLC, 7 Creek Bend Court, Newark, Delaware 19711
(US).

(74) Agent: **ROSEDALE, Jeffrey H.** et al.; BAKER-
HOSTETLER, Cira Centre 12th Floor, 2929 Arch Street,
Philadelphia, Pennsylvania 19104 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,

(54) Title: ADENOVIRAL VECTORS ENCODING HEPATITIS B VIRAL ANTIGENS FUSED TO HERPES VIRUS GLYCOPROTEIN D AND METHODS OF USING THE SAME

FIG. 25B



(57) Abstract: Provided herein are non-naturally occurring variants of the hepatitis B virus (HBV) Core protein, the HBV polymerase N-terminal domain, and the HBV polymerase C-terminal domain, as well as immunogenic fragments thereof. Fusion proteins comprising the HBV variants fused to a herpes simplex virus (HSV) glycoprotein (gD) sequence, as well as methods of using the fusion proteins, are also provided.

[Continued on next page]

NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*